Cas:880262-14-6 [(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate manufacturer & supplier

Chemical Name:[(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate

CAS.NO:880262-14-6

Synonyms:[(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate

Molecular Formula:C₇₇H₇₀BF₂₄IrNO₃P

Molecular Weight:1747.35000

HS Code:

Physical and Chemical Properties:

Melting point:160-161°C

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:57.70000

Exact Mass:1747.44000

LogP:22.72760

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like [(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate Use and application,[(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate technical grade,usp/ep/jp grade.

Related News: Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage. [(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. [(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate supplier If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. [(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate vendor The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. [(1,2,5,6-eta)-1,5-Cyclooctadiene][1-[(4R,5R)-4,5-dihydro-5-methyl-2-phenyl-4-oxazolyl]-2-phenyl-1-(phenylmethyl)ethyl dicyclohexylphosphinite]iridium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate factory The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.